TransparentRx parent reaches confidential settlement ending litigation

FiduciaryRx LLC, the company behind TransparentRx, said Aug. 20 that it reached a confidential settlement with Transparency Rising Corp. that resolves their litigation. The company says it will keep focusing on fiduciary pharmacy benefit administration for self-funded employers and plans to keep investing in the TransparentRx brand.

Why it matters: - The settlement removes a legal overhang for FiduciaryRx LLC as it tries to keep building its TransparentRx business. - The company’s core pitch centers on helping self-funded employers control pharmacy benefit costs and increase accountability in how those dollars are managed. - TransparentRx is positioning itself around fiduciary standards of care for plan sponsors, a theme that can shape how employers evaluate pharmacy benefit managers and related administrators.

What happened: - FiduciaryRx LLC announced on Aug. 20, 2026 that it reached a confidential settlement with Transparency Rising Corp., formerly Transparency-Rx Corp. - The agreement resolves litigation between the two parties. - FiduciaryRx said it will not comment on the settlement terms because they are confidential. - Tyrone Squires, founder and managing director of FiduciaryRx, said the company is moving its attention back to helping employers protect pharmacy benefit dollars and hold managers of those dollars to a fiduciary standard of care.

The details: - FiduciaryRx will continue investing in its clients and the TransparentRx brand. - The company says it helps self-funded employers strengthen oversight of decisions that affect plan performance and member care. - Squires said employers should know how their pharmacy benefit dollars are spent and who benefits from those decisions. - FiduciaryRx is based in Las Vegas, Nevada. - The company operates under the TransparentRx brand and describes itself as providing fiduciary pharmacy benefit administration for self-funded employers. - More information is available on TransparentRx's LinkedIn page.

Between the lines: - The resolution suggests FiduciaryRx wants the market to focus on its operating model rather than the dispute. - The company is leaning hard into transparency and accountability as a differentiator in a crowded benefits-administration market. - The messaging also reflects broader pressure on employers to scrutinize pharmacy benefit spending and the incentives behind it.

What's next: - FiduciaryRx said it will keep investing in the TransparentRx brand and in its clients. - The company is also continuing to push the industry toward what it calls a higher accountability standard. - Any broader details about the settlement are unlikely to emerge unless one of the parties changes its position on confidentiality.